Two novel targets have been identified by the group of Kositza et al. on bladder cancer cell lines T24, RT112, and UMUC3: MCM6 and KIFC1 are two of the targetable genes that confer resistance to CDK4/6 inhibitors, and the combination of palbociclib and other MCM6/KIFC1 inhibitors, including ciprofloxacin, resulted in a synergistic effect in terms of delayed tumor growth [96]. Here, KIFC1 is linked to urinary bladder cancer.